Therapeutic potential for HDAC inhibitors in the heart

Annu Rev Pharmacol Toxicol. 2012;52:303-19. doi: 10.1146/annurev-pharmtox-010611-134712. Epub 2011 Sep 26.

Abstract

Reversible protein acetylation provides a central mechanism for controlling gene expression and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are currently approved for the treatment of human cancer, and numerous follow-on compounds are in clinical development for oncology and non-oncology indications. The inhibitors target members of a family of enzymes known as histone deacetylases (HDACs). Surprisingly, HDAC inhibitors have also been shown to be efficacious in preclinical models of heart failure. This review highlights roles of HDACs in the heart and the therapeutic potential of HDAC inhibitors for the treatment of heart failure.

Publication types

  • Review

MeSH terms

  • Acetylation
  • Animals
  • Drug Evaluation, Preclinical
  • Heart / drug effects*
  • Heart / physiopathology
  • Heart Failure / drug therapy*
  • Heart Failure / pathology
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Histone Deacetylases / metabolism*
  • Histones / metabolism*
  • Humans
  • Models, Animal
  • Models, Biological
  • Ventricular Remodeling / drug effects

Substances

  • Histone Deacetylase Inhibitors
  • Histones
  • Histone Deacetylases